2025-09-22

Artivila Announces Successful Completion of ARD-885 Phase I Clinical Study

ShengZhen, Sep 22, 2025, Artivila , a clinical stage biopharmaceutical company (“Artivila”), announced the successful completion of a Phase I clinical study of ARD-885, a novel Class 1 small molecule drug developed by the company for the treatment of auto

2024-12-11

Artivila Biopharma Announces Clearances of IND Applications for ARD-885 by China

ShenZhen, Guangdong, China. December 11, 2024- Artivila Biopharma today announced that the Chinese NMPA and the United States FDA have approved its IND applications for its small molecule new drug ARD-885 for the treatment of rheumatoid arthritis.